Jeffrey Varner

Prof. Jeffrey Varner

School of Chemical and Biomolecular Engineering, 244 Olin Hall, Cornell University, Ithaca, NY 14853, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
ACAnirikh Chakrabarti
Anirikh Chakrabarti
ACAaron W. Chen
Aaron W. Chen
Jeffrey VarnerJeffrey Varner
Jeffrey Varner

20 July 2007 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
DLDeyan Luan
Deyan Luan
MZMichael Zai
Michael Zai
Jeffrey VarnerJeffrey Varner
Jeffrey Varner
The role that mechanistic mathematical modeling and systems biology will play in molecular medicine and clinical development remains uncertain. In this study, mathematical modeling and sensitivity analysis were used to explore the working hypothesis that mechanistic models of human cascades, despite model uncertainty, can be computationally screened for points of fragility, and that these sensitive mechanisms could serve as therapeutic targets. We tested our working hypothesis by screening a model of the well-studied coagulation cascade, developed and validated from literature. The predicted sensitive mechanisms were then compared with the treatment literature. The model, composed of 92 proteins and 148 protein–protein interactions, was validated using 21 published datasets generated from two different quiescent in vitro coagulation models. Simulated platelet activation and thrombin generation profiles in the presence and absence of natural anticoagulants were consistent with measured values, with a mean correlation of 0.87 across all trials. Overall state sensitivity coefficients, which measure the robustness or fragility of a given mechanism, were calculated using a Monte Carlo strategy. In the absence of anticoagulants, fluid and surface phase factor X/activated factor X (fX/FXa) activity and thrombin-mediated platelet activation were found to be fragile, while fIX/FIXa and fVIII/FVIIIa activation and activity were robust. Both anti-fX/FXa and direct thrombin inhibitors are important classes of anticoagulants; for example, anti-fX/FXa inhibitors have FDA approval for the prevention of venous thromboembolism following surgical intervention and as an initial treatment for deep venous thrombosis and pulmonary embolism. Both in vitro and in vivo experimental evidence is reviewed supporting the prediction that fIX/FIXa activity is robust. When taken together, these results support our working hypothesis that computationally derived points of fragility of human relevant cascades could be used as a rational basis for target selection despite model uncertainty. To date, mechanistic mathematical modeling, in general, has not played a significant role in the development of new therapies for cancer, cardiovascular diseases, or the treatment of acute events like thrombosis during surgery. One critical issue often cited for the lack of interest has been uncertainty; the conventional wisdom is that the data requirement to fully determine and validate large mechanistic models is just too high. We show, using tools from systems biology and sensitivity analysis, that it may be possible to extract qualitative information about the critical elements of human relevant cascades despite model uncertainty. Using a mechanistic model of the human coagulation cascade, we were able to identify the critical mechanisms controlling the formation of thrombin, a key protein active in the formation of blood clots. We were further able to support the hypothesis that the critical mechanisms identified by our analysis could serve as drug targets by comparing our findings with the thrombosis treatment literature and with current clinical trials. The results support the notion that mechanistic models could be used, despite model uncertainty, to pinpoint key mechanisms in complex networks, and that these mechanisms could potentially be therapeutically exploited.

30 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RTRyan Tasseff
Ryan Tasseff
HJHolly A. Jensen
Holly A. Jensen
JCJohanna Congleton
Johanna Congleton
DDDavid Dai
David Dai
KRKatharine V. Rogers
Katharine V. Rogers
Jeffrey VarnerJeffrey Varner
Jeffrey Varner
In this study, we present an effective model All-Trans Retinoic Acid (ATRA)-induced differentiation of HL-60 cells. The model describes reinforcing feedback between an ATRA-inducible signalsome complex involving many proteins including Vav1, a guanine nucleotide exchange factor, and the activation of the mitogen activated protein kinase (MAPK) cascade. We decomposed the effective model into three modules; a signal initiation module that sensed and transformed an ATRA signal into program activation signals; a signal integration module that controlled the expression of upstream transcription factors; and a phenotype module which encoded the expression of functional differentiation markers from the ATRA-inducible transcription factors. We identified an ensemble of effective model parameters using measurements taken from ATRA-induced HL-60 cells. Using these parameters, model analysis predicted that MAPK activation was bistable as a function of ATRA exposure. Conformational experiments supported ATRA-induced bistability. Additionally, the model captured intermediate and phenotypic gene expression data. Knockout analysis suggested Gfi-1 and PPARg were critical to the ATRAinduced differentiation program. These findings, combined with other literature evidence, suggested that reinforcing feedback is central to hyperactive signaling in a diversity of cell fate programs.

25 September 2012 in Annals of Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
ACAnirikh Chakrabarti
Anirikh Chakrabarti
SVScott Verbridge
Scott Verbridge
ASAbraham D. Stroock
Abraham D. Stroock
CFClaudia Fischbach
Claudia Fischbach
Jeffrey VarnerJeffrey Varner
Jeffrey Varner

26 June 2018 in ACS Synthetic Biology
Verified
Journal Article
Closed access
MVMichael Vilkhovoy
Michael Vilkhovoy
NHNicholas Horvath
Nicholas Horvath
CSChe-Hsiao Shih
Che-Hsiao Shih
JWJoseph A. Wayman
Joseph A. Wayman
KCKara Calhoun
Kara Calhoun
Jeffrey VarnerJeffrey Varner
Jeffrey Varner

1 June 2020 in Metabolic Engineering Communications
Verified
Journal Article
Open access
NHNicholas Horvath
Nicholas Horvath
MVMichael Vilkhovoy
Michael Vilkhovoy
JWJoseph A. Wayman
Joseph A. Wayman
KCKara Calhoun
Kara Calhoun
JSJames Swartz
James Swartz
Jeffrey VarnerJeffrey Varner
Jeffrey Varner
In this study, we developed a dynamic mathematical model of E. coli cell-free protein synthesis (CFPS). Model parameters were estimated from a dataset consisting of glucose, organic acids, energy species, amino acids, and protein product, chloramphenicol acetyltransferase (CAT) measurements. The model was successfully trained to simulate these measurements, especially those of the central carbon metabolism. We then used the trained model to evaluate the performance, e.g., the yield and rates of protein production. CAT was produced with an energy efficiency of 12%, suggesting that the process could be further optimized. Reaction group knockouts showed that protein productivity was most sensitive to the oxidative phosphorylation and glycolysis/gluconeogenesis pathways. Amino acid biosynthesis was also important for productivity, while overflow metabolism and TCA cycle affected the overall system state. In addition, translation was more important to productivity than transcription. Finally, CAT production was robust to allosteric control, as were most of the predicted metabolite concentrations; the exceptions to this were the concentrations of succinate and malate, and to a lesser extent pyruvate and acetate, which varied from the measured values when allosteric control was removed. This study is the first to use kinetic modeling to predict dynamic protein production in a cell-free E. coli system, and could provide a foundation for genome scale, dynamic modeling of cell-free E. coli protein synthesis.